Assessing CorMedix (CRMD) Valuation After Its Strong Multi‑Year Share Price Gains
CorMedix (CRMD) has been quietly rewarding patient shareholders, with the stock up about 41% year to date and more than doubling over the past 3 years, even after a softer past 3 months.
See our latest analysis for CorMedix.
The latest 7 day share price return of 12.6% suggests momentum is rebuilding after a weaker 90 day stretch, and that sits alongside a striking 3 year total shareholder return of 183.4% from a base that was far lower than today’s 11.62 dollar share price.
If CorMedix’s move has sparked your interest in healthcare, this could be a good moment to explore other potential winners using our curated screen of healthcare stocks.
With CorMedix now trading well below consensus targets yet boasting strong multi year gains, investors face a key question: is there still meaningful upside ahead or has the market already priced in its future growth?
Most Popular Narrative: 38.8% Undervalued
With CorMedix last closing at 11.62 dollars against a narrative fair value of 19 dollars, the story leans heavily toward upside potential and aggressive growth assumptions.
The acquisition of Melinta Therapeutics immediately diversifies and stabilizes CorMedix's revenue base by adding 125 to 135 million dollars in expected 2025 revenue from multiple acute care and infectious disease products, which should support top line growth and enhance earnings visibility. Ongoing and pipeline expansions (such as DefenCath's Phase III trials for additional indications and the potential REZZAYO label expansion) target growing patient populations driven by aging demographics and increased chronic disease prevalence, positioning CorMedix to capitalize on long term increases in demand and deliver sustained revenue growth.
Curious how robust revenue expansion, richer margins and a sharply lower future earnings multiple still point to upside from here? See which bold forecasts anchor that 19 dollar fair value.
Result: Fair Value of $19 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, elevated integration and regulatory risks around Melinta and key late stage trials mean execution missteps could quickly challenge those upbeat growth assumptions.
Find out about the key risks to this CorMedix narrative.
Build Your Own CorMedix Narrative
If this take does not quite align with your view and you would rather test the numbers yourself, you can build a complete narrative in just a few minutes, starting with Do it your way.
A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
Ready for your next investing move?
Do not stop with just one stock. Use the Simply Wall Street Screener to uncover fresh ideas tailored to growth, value, and long term wealth building.
- Capitalize on market mispricing by targeting companies trading below their estimated cash flow value through these 899 undervalued stocks based on cash flows.
- Ride structural trends by focusing on innovation leaders in automation, data, and software with these 27 AI penny stocks.
- Strengthen your income strategy by seeking reliable, above average yields using these 15 dividend stocks with yields > 3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com